Note: Descriptions are shown in the official language in which they were submitted.
CA 02868416 2014-09-24
WO 2013/158810 PCT/US2013/037046
1
IMMEDIATE RELEASE PHARMACEUTICAL COMPOSITIONS WITH
ABUSE DETERRENT PROPERTIES
CROSS-REFERENCE TO RELATED APPLICATIONS
100011 This application
claims the benefit of U.S. Provisional Application
No. 61/625,718 filed April 18, 2012, which is incorporated herein in its
entirety.
FIELD OF THE INVENTION
[0002] The present disclosure generally relates to pharmaceutical
compositions that provide immediate release of active ingredients and have
abuse
deterrent properties.
BACKGROUND OF THE INVENTION
[0003] Abuse of prescription drugs (particularly opioids) has become a
serious societal problem. Such abuse places an enormous economic burden on
society due to increased health care, work place, and criminal justice costs.
Several
routes of administration are commonly attempted by abusers. For example, the
oral
solid dosage form may be crushed or pulverized into a powder and administered
intranasally (i.e., snorted) or dissolved in a suitable solvent (e.g., water)
and
administered parenterally (i.e., injected intravenously).
[0004] Attempts have been made to diminish the abuse of opioid solid
dosage forms. One approach has been to include in the dosage form an opioid
antagonist that is not orally active but will substantially block the
analgesic effects of
the opioid if one attempts to dissolve the opioid and administer it
parenterally.
Another approach has been to include gel-forming high molecular weight
polymers
that confer plasticity to the dosage form rendering them difficult to crush
and
pulverize into a powder. These high molecular weight polymers, however, retard
the
release of the active ingredient from the dosage forms, making them unsuitable
for
immediate release formulations.
[0005] Thus, there is a need for oral solid dosage forms that provide
immediate release of the active ingredient yet are resistant to abuse.
CA 02868416 2014-09-24
WO 2013/158810
PCT/US2013/037046
2
SUMMARY OF THE INVENTION
[0006] The present disclosure, therefore, provides a pharmaceutical
composition comprising at least one active pharmaceutical ingredient (API) or
a
pharmaceutically acceptable salt thereof, at least one low molecular weight
water-
soluble polymer, at least one polyglycol, at least one polysaccharide, at
least one
clay mineral, and, optionally, an effervescent system.
[0007] Another aspect of the present disclosure provides a process
for
preparing a solid dosage. The process comprises forming a mixture comprising
at
least one low molecular weight water-soluble polymer, at least one polyglycol,
at
least one polysaccharide, at least one clay mineral, and, optionally, an
effervescent
system. The process further comprises forming the mixture into a solid dosage
unit,
and heating the solid dosage unit to yield the solid dosage form.
[0008] Other aspects and iterations of the disclosure are described
in
more detail below.
REFERENCE TO COLOR FIGURES
[0009] The patent or application file contains at least one drawing
executed in color. Copies of this patent or patent application publication
with color
drawings will be provided by the Office upon request and payment of the
necessary
fee.
BRIEF DESCRIPTION OF THE FIGURES
[0010] FIG. 1 presents SEM images of L-(+)-tartaric acid particles
(A);
L-(+)-tartaric acid particles coated with Pluronic F127 (B); and Pluronic Fl
27-coated
L-(+)-tartaric acid particles blended with talc (C).
[0011] FIG. 2 shows the surface of a Pluronic F127-coated tartaric
acid
particle blended with talc. Elemental mapping shows that the majority of the
surface
is covered with talc, with limited Pluronic F127-coated surface visible. The
carbon
element of Pluronic F127 is denoted in red in panel (A) or purple in panel
(B).
DETAILED DESCRIPTION OF THE INVENTION
[0012] The present disclosure provides pharmaceutical compositions
and processes for making solid dosage pharmaceutical compositions that provide
CA 02868416 2014-09-24
WO 2013/158810
PCT/US2013/037046
3
rapid release of the active ingredients and have abuse deterrent properties.
In
addition to one or more pharmaceutically active ingredients, the compositions
disclosed herein comprise at least one low molecular weight water-soluble
polymer,
at least one polyglycol, at least one polysaccharide, at least one clay
mineral, and an
optional effervescent system. It was discovered that the combination of
excipients
comprising the compositions disclosed herein provides immediate release of the
active ingredient(s) and makes the compositions resistant to crushing into
fine
powders and/or extracting with suitable solvents.
(I) Pharmaceutical Compositions
[0013] One aspect of the present disclosure provides immediate
release pharmaceutical compositions with abuse deterrent properties.
(a) Components of the Compositions
[0014] The pharmaceutical compositions disclosed herein comprise at
least one pharmaceutically active ingredient (API) or a pharmaceutically
acceptable
salt thereof and a blend of pharmaceutically acceptable excipients. The
excipients
comprise low molecular weight water-soluble polymers, polyglycols,
polysaccharides, clay minerals, and, optionally, effervescent systems. It is
the
combination of these excipients that provides the immediate release and abuse
deterrent properties of the compositions.
(i) Low molecular weight water-soluble polymers
[0015] The pharmaceutical compositions comprise at least one low
molecular weight water-soluble polymer. The term "water-soluble polymer," as
used
herein, refers to polymers that are soluble or swellable in aqueous solutions.
Some
water-soluble polymers, however, may also be soluble in nonaqueous solvents
such
as the lower alcohols (e.g., methanol or ethanol).
[0016] The water-soluble polymer may be synthetic, semi-synthetic,
or
naturally-occurring. Non-limiting examples of suitable water-soluble polymers
include polyalkylene oxides such as polyethylene oxides (PEO); cellulose
ethers
such as hydroxypropyl cellulose, methyl cellulose, hydroxymethyl cellulose,
hydroxyethyl cellulose, hydroxypropylmethyl cellulose, carboxymethyl
cellulose, and
the like; polyolefinic alcohols such as polyvinyl alcohols: polyvinyl lactams
such as
CA 02868416 2014-09-24
WO 2013/158810
PCT/US2013/037046
4
polyvinylpyrrolidone, polvinyl caprolactam, and the like; and polycarboxylic
acids,
such as polyacrylic acids.
[0017] As used herein, the term "low molecular weight polymer"
refers
to a polymer having an approximate molecular weight of no more than about
300,000 Da. In various embodiments, the approximate molecular weight of the
low
molecular weight polymer may range from about 300,000 to about 250,000 Da,
from
about 250,000 to about 200,000 Da, from about 200,000 to about 150,000 Da,
from
about 150,000 to about 100,000 Da, from 100,000 to about 75,000 Da, from about
75,000 to about 50,000 Da, from about 50,000 to about 25,000 Da, or from about
25,000 to about 1000 Da.
[0018] In certain embodiments, the low molecular weight water-
soluble
polymer may be a polyethylene oxide. In an exemplary embodiment, the
polyethylene oxide may have an approximate molecular weight of about 100,000
Da.
[0019] The amount of low molecular weight water-soluble polymer
present in the composition can and will vary depending upon the desired
properties
of the composition, as well as the identity and amounts of other components
present
in the composition. In general, the amount of low molecular weight polymer
present
in the composition may range from about 5% to about 60% by weight of the
composition. In various embodiments, the amount of low molecular weight
polymer
present in the composition may range from about 5% to about 15%, from about
15%
to about 25%, from about 25% to about 40%, or from about 40% to about 60% by
weight of the total weight of the composition. In exemplary embodiments, the
amount of low molecular weight polymer present in the composition may range
from
about 20% to about 50% by weight of the total weight of the composition,
(ii) Polyglycol
[0020] The pharmaceutical compositions also comprise at least one
polyglycol. Suitable polyglycols have wax-like properties in the solid state
and
emulsification properties in the liquid state. Thus, the presence of the
polyglycol in
the compositions may provide stickiness to solid dosage forms such that they
are
difficult to crush into fine powders. Additionally, the polyglycol may
facilitate the
suspension of clay mineral particles in mixtures formed when the
pharmaceutical
compositions disclosed here are mixed with small volumes of suitable solvents.
CA 02868416 2014-09-24
WO 2013/158810
PCT/US2013/037046
[0021] Non-limiting examples of suitable polyglycols include
copolymers of ethylene glycol and propylene glycol, polyethylene glycols,
polypropylene glycols, polyethylene-polypropylene glycols, polyoxyethylene
alkyl
esters, polyoxyethylene sorbitan fatty acid esters, polyoxyethylene stearates,
and
combinations thereof. In one embodiment, the polyglycol may be a copolymer of
ethylene glycol and propylene glycol. Such copolymers are also known as
poloxamers and are available under the tradenames PLURONIC or KOLLIPHORTM.
For example, the polyglycol may be PLURONIC F38, F68, F77, F87, F88, F98,
F108, F127, or combinations thereof. Other than polyglycols, self-emulsifying
waxes
may also be used. An example of a suitable self-emulsifying wax is Emulsifying
Wax
NF, which is a blend of cetearyl alcohol, polysorbate 60, PEG-150 stearate,
and
steareth-20 (which is a synthetic polymer composed of PEG and stearyl
alcohol).
[0022] In exemplary embodiments, the polyglycol may be PLURONIC
F127 (which is also known as poloxamer 407 or KOLL1PHORTM P407). In another
preferred embodiment, the polyglycol may be PLURONIC F68 (which is also known
as poloxamer 188 or KOLLIPHORTM P188). In one exemplary embodiment, the
polyglycol may comprise a combination of PLURONIC F68 and PLURONIC F127.
[0023] The amount of the polyglycol present in the composition can
and
will vary depending upon the desired properties of the composition. In
general, the
amount of the polyglycol present in the composition may range from about 5% to
about 50% by weight of the composition. In various embodiments, the amount of
the
polyglycol present in the composition may range from about 5% to about 10%,
from
about 10% to about 20%, from about 20% to about 30%, from about 30% to about
40%, or from about 40% to about 50% by weight of the total weight of the
composition. In exemplary embodiments, the amount of the polyglycol present in
the
composition may range from about 10% to about 45% by weight of the
composition.
(iii) Polysaccharide
[0024] The pharmaceutical compositions disclosed herein also
comprise at least one polysaccharide. In general, the polysaccharide functions
as
an emulsifying agent. For example, the polysaccharide may facilitate the
suspension
of clay mineral particles in dispersions formed when the pharmaceutical
composition
disclosed herein is mixed with a small volume of a suitable solvent. A variety
of
polysaccharides may be included in the pharmaceutical compositions. Suitable
CA 02868416 2014-09-24
WO 2013/158810
PCT/US2013/037046
6
polysaccharides include, without limit, celluloses, starches, pectins,
chitins, gums
(i.e., polysaccharides derived from plants or microbes), combinations thereof,
and
derivatives thereof. In exemplary embodiments, the polysaccharide may be a
gum.
Non-limiting examples of suitable gums include xanthan gum, acacia gum, diutan
gum, gellan gum, guar gum, fenugreek gum, locust bean gum, pullulan, welan
gum,
or combinations thereof. In exemplary embodiments, the polysaccharide may be
xanthan gum.
[0025] The mesh size of the polysaccharide may can and will vary.
For
example, the mesh size may range from coarse (e.g., 45 mesh) to fine (e.g.,
200
mesh). In one embodiment, the polysaccharide may be xanthan gum having a mesh
size of about 60.
[0026] The amount of the polysaccharide in the composition can and
will vary depending upon the desired properties of the composition. In
general, the
amount of polysaccharide present in the composition may range from about 1% to
about 10% by weight of the total weight of the composition. In various
embodiments,
the amount of polysaccharide present in the composition may range from about
1%
to about 3%, from about 3% to about 6%, or from about 6% to about 10% by
weight
of the total weight of the composition. In exemplary embodiments, the amount
of
polysaccharide present in the composition may range from about 2% to about 6%
by
weight of the total weight of the composition.
(iv) Clay mineral
[0027] The pharmaceutical compositions disclosed herein also
comprise at least one clay mineral. As used herein, a "clay mineral" refers to
a
hydrated aluminum phyllosilicate or a hydrated magnesium silicate. In general,
clay
minerals comprise small insoluble particles. Additionally, some clay minerals
are
absorbent and swell when wet. For example, sodium bentonite can absorb water
several times its dry weight and swell to approximately 5-10 times its own
volume.
Thus, mixing a clay mineral with water or another solvent forms a colloidal
dispersion, i.e., the clay mineral particles are visible and stay suspended
for
extended periods of time.
[0028] A variety of clay minerals are suitable for inclusion in the
pharmaceutical composition. Non-limiting examples of suitable clay minerals
include
bentonites (e.g., sodium bentonite, calcium bentonite, potassium bentonite),
CA 02868416 2014-09-24
WO 2013/158810
PCT/US2013/037046
7
kaolinites, nontronites, montmorillonites, pyrophyllites, saponites,
sauconites,
vermiculites, talc, and combinations thereof. In one exemplary embodiment, the
clay
mineral may be a combination of sodium bentonite and talc. The talc may be
micronized. In another exemplary embodiment, the clay mineral may be sodium
bentonite.
[0029] The amount of the clay mineral present in the composition
can
and will vary depending upon the desired properties of the composition. In
general,
the amount of the clay mineral present in the composition may range from about
1%
to about 30% by weight of the total weight of the composition. In various
embodiments, the amount of the clay mineral present in the composition may
range
from about 1% to about 5%, from about 5% to about 10%, from about 10% to about
20%, or from about 20% to about 30% by weight of the composition. In exemplary
embodiments, the amount of clay mineral present in the composition may range
from
about 5% to about 25% by weight of the composition.
(v) Optional effervescent system
[0030] The pharmaceutical compositions disclosed herein may
optionally comprise an effervescent system. As used herein, an "effervescent
system" refers to a system generally comprising an acid component and a base
component, wherein the system liberates carbon dioxide upon contact with an
aqueous solution. Without being bound by any particular theory, it is believed
that
the effervescent system facilitates rapid dissolution of an active ingredient
from the
composition.
[0031] The acid component of the effervescent system may be an
organic acid, an inorganic acid, or combinations thereof. Non-limiting
examples of
suitable acids include adipic acid, ascorbic acid, benzoic acid, citric acid,
fumaric
acid, glutaric acid, lactic acid, lauric acid, malic acid, maleic acid,
malonic acid, oxalic
acid, phthalic acid, sorbic acid, succinic acid, tartaric acid, ammonium
phosphate,
potassium bitartrate, potassium phosphate, dipotassium phosphate, disodium
pyrophosphate, sodium acid pyrophosphate, sodium phosphate, disodium
phosphate, and combinations thereof. In one exemplary embodiment, the acid
component of the effervescent system may be a combination of citric acid and
CA 02868416 2014-09-24
WO 2013/158810
PCT/US2013/037046
8
tartaric acid. In another exemplary embodiment, the acid component of the
effervescent system may be tartaric acid.
[00321 The base component of the effervescent system may be a
bicarbonate, a carbonate, or a combination thereof. In various embodiments,
the
base may be an alkali metal bicarbonate, an alkaline earth metal bicarbonate,
an
alkali metal carbonate, an organic carbonate, or combinations thereof. Non-
limiting
examples of suitable bases include ammonium bicarbonate, calcium bicarbonate,
lithium bicarbonate, magnesium bicarbonate, potassium bicarbonate, sodium
bicarbonate, arginine carbonate, ammonium carbonate, calcium carbonate, lysine
carbonate, potassium magnesium carbonate, sodium carbonate, sodium glycine
carbonate, sodium sesquicarbonate, zinc carbonate, and combinations thereof.
In
exemplary embodiments, the base component of the effervescent system may be an
alkali metal bicarbonate (such as sodium bicarbonate or potassium
bicarbonate), an
alkali metal carbonate (such as sodium carbonate or potassium carbonate), or
combinations thereof. In one exemplary embodiment, the base component may be
sodium bicarbonate. In another exemplary embodiment, the base component may
be heat-treated sodium bicarbonate (for example EfferSoda 12).
[00331 The amount of the effervescent system present in the
composition can and will vary depending upon the desired properties of the
composition. In general, in embodiments in which the effervescent system is
present, the amount of the effervescent system may range from about 5% to
about
70% by weight of the composition. For example, the amount of the effervescent
system present in the composition may range from about 5% to about 10%, from
about 10% to about 20%, from about 20% to about 30%, from about 30% to about
40%, from about 40% to about 50%, from about 50% to about 60%, or from about
60% to about 70% by weight of the composition. In exemplary embodiments in
which the pharmaceutical composition comprises the effervescent system, the
amount of the effervescent system present in the composition may range from
about
15% to about 50% by weight of the composition.
[0034] The mole to mole ratio of the acid component to the base
component in the effervescent system may also vary depending upon the identity
of
the acid and base components. In general, the mole to mole ratio of the acid
component to the base component in the effervescent system may range from
about
1:3 to about 3:1. For example, the mole to mole ratio of the acid component to
the
CA 02868416 2014-09-24
WO 2013/158810 PCT/US2013/037046
9
base component in the effervescent system may be about 1:3, 1:2, 1:1, 2:1,
3:1, or
any ratio in-between. In am exemplary embodiment, the mole to mole ratio of
the
acid component to the base component in the effervescent system may be about
1:2.
(vi) APIs
[0035] The pharmaceutical compositions disclosed herein may
comprise a variety of APIs. Suitable APIs include, without limit, opioid
analgesic
agents (e.g., adulmine, alfentanil, allomptopine, allylprodine, alphaprodine,
anileridine, aporphine, benzylmorphine, berberine, bicuculine,
bicucineõbezitramide,
buprenorphine, bulbocaprine, butorphanol, clonitazene, codeine, desornorphine,
dextromorannide, dezocine, diampromide, diamorphone, dihydrocodeine,
dihydromorphine, dimenoxadol, dimepheptanol, dimethylthiambutene, dioxaphetyl
butyrate, dipipanone, eptazocine, ethoheptazine, ethylmethylthiambutene,
ethylmorphine, etonitazene, fentanyl, heroin, hydrocodone, hydromorphone,
hydroxypethidine, isomethadone, ketobemidone, levorphanol,
levophenacylmorphan,
lofentanil, meperidine, meptazinol, metazocine, methadone, metopon, morphine,
myrophine, narceine, nicomorphine, norlevorphanol, normethadone, nalorphine,
nalbuphene, normorphine, norpipanone, opium, oxycodone, oxymorphone,
papaveretum, pentazocine, phenadoxone, phenomorphan, phenazocine,
phenoperidine, piminodine, piritramide, propheptazine, promedol, properidine,
propoxyphene, sufentanil, tapentadol, tilidine, and tramadol); non-opioid
analgesic
agents (e.g., acetylsalicylic acid, acetaminophen, paracetamol, ibuprofen,
ketoprofen, indomethacin, diflunisol, naproxen, ketorolac, dichlophenac,
tolmetin,
sulindac, phenacetin, piroxicam, and mefamanic acid); anti-inflammatory agents
(e.g., glucocorticoids such as alclometasone, fluocinonide,
methylprednisolone,
triamcinolone and dexamethasone; non-steroidal anti-inflammatory agents such
as
celecoxib, deracoxib, ketoprofen, lumiracoxib, meloxicam, parecoxib,
rofecoxib, and
valdecoxib); antitussive agents (e.g., dextromethorphan, codeine, hydrocodone,
caramiphen, carbetapentane, and dextromethorphan); antipyretic agents (e.g.,
acetylsalicylic acid and acetaminophen); antibiotic agents (e.g.,
aminoglycosides
such as, amikacin, gentamicin, kanamycin, neomycin, netilmicin, streptomycin,
and
tobramycin; carbecephem such as loracarbef; carbapenems such as certapenem,
imipenem, and meropenem; cephalosporins such as cefadroxil cefazolin,
cephalexin,
CA 02868416 2014-09-24
WO 2013/158810 PCT/US2013/037046
cefaclor, cefamandole, cephalexin, cefoxitin, cefprozil, cefuroxime, cefixime,
cefdinir,
cefditoren, cefoperazone, cefotaxi me, cefpodoxime, ceftazidime, ceftibuten,
ceftizoxime, and ceftriaxone; macrolides such as azithromycin, clarithromycin,
dirithromycin, erythromycin, and troleandomycin; monobactam; penicillins such
as
amoxicillin, ampicillin, carbenicillin, cloxacillin, dicloxacillin, nafcillin,
oxacillin,
penicillin G, penicillin V, piperacillin, and ticarcillin; polypeptides such
as bacitracin,
colistin, and polymyxin B; quinolones such as ciprofloxacin, enoxacin,
gatifloxacin,
levofloxacin, lomefioxacin, moxifioxacin, norfloxacin, ofioxacin, and
trovafloxacin;
sulfonamides such as mafenide, sulfacetamide, sulfamethizole, sulfasalazine,
sulfisoxazole, and trimethoprim-sulfamethoxazole; tetracyclines such as
demeclocycline, doxycycline, minocycline, and oxytetracycline); antimicrobial
agents
(e.g., ketoconazole, arnoxicillin, cephalexin, miconazole, econazole,
acyclovir, and
nelfinavir); antiviral agents (e.g., acyclovir, gangciclovir, oseltamivir, and
relenza);
steroids (e.g., estradiol, testosterone, cortisol, aldosterone, prednisone,
and
cortisone); amphetamine stimulant agents (e.g., amphetamine and amphetamine-
like
drugs); non-amphetamine stimulant agents (e.g., methylphenidate, nicotine, and
caffeine); laxative agents (e.g., bisacodyl, casanthranol, senna, and castor
oil); anti-
nausea agents (e.g., dolasetron, granisetron, ondansetron, tropisetron,
meclizine,
and cyclizine); anorexic agents (e.g., fenfluramine, dexfenfluramine,
mazindol,
phentermine, and aminorex); antihistaminic agents (e.g., phencarol,
cetirizine,
cinnarizine, ethamidindole, azatadine, brompheniramine, hydroxyzine, and
chlorpheniramine); antiasthmatic agents (e.g., zileuton, montelukast,
omalizumab,
fluticasone, and zafirlukast); antidiuretic agents (e.g., desmopressin,
vasopressin,
and lypressin); an antiflatulant agent (e.g., simethicone); antimigraine
agents (e.g.,
naratriptan, frovatriptan, eletriptan, dihydroergotamine, zolmitriptan,
almotriptan, and
sumatriptan); antispasmodic agents (e.g., dicyclomine, hyoscyamine, and
peppermint oil); antidiabetic agents (e.g., methformin, acarbose, miglitol,
pioglitazone, rosiglitazone, troglitazone, nateglinide, repaglinide,
mitiglinide,
saxagliptin, sitagliptine, vildagliptin, acetohexamide, chlorpropamide,
gliclazide,
glimepiride, glipizide, glyburide, tolazamide, and tolbutamide); respiratory
agents
(e.g., albuterol, ephedrine, metaproterenol, and terbutaline); sympathomimetic
agents (e.g., pseudoephedrine, phenylephrine, phenylpropanolamine,
epinephrine,
norepinephrine, dopamine, and ephedrine); H2 blocking agents (e.g.,
cimetidine,
famotidine, nizatidine, and ranitidine); antihyperlipidemic agents (e.g.,
clofibrate,
CA 02868416 2014-09-24
WO 2013/158810 PCT/US2013/037046
11
cholestyramine, colestipol, fluvastatin, atorvastatin, genfibrozil,
lovastatin, niacin,
pravastatin, fenofibrate, colesevelam, and simvastatin); antihypercholesterol
agents
(e.g., lovastatin, simvastatin, pravastatin, fluvastatin, atorvastatin,
cholestyramine,
colestipol, colesevelam, nicotinic acid, gemfibrozil, and ezetimibe);
cardiotonic
agents (e.g., digitalis, ubidecarenone, and dopamine); vasodilating agents
(e.g.,
nitroglycerin, captopril, dihydralazine, diltiazem, and isosorbide dinitrate);
vasoconstricting agents (e.g., dihydroergotoxine and dihydroergotamine);
anticoagulants (e.g., warfarin, heparin, and Factor Xa inhibitors); sedative
agents
(e.g., amobarbital, pentobarbital, secobarbital, clomethiazole,
diphenhydramine
hydrochloride, and alprazolam); hypnotic agents (e.g., zaleplon, zolpidem,
eszopiclone, zopiclone, chloral hydrate, and clomethiazole); anticonvulsant
agents
(e.g., lamitrogene, oxycarbamezine, phenytoin, mephenytoin, ethosuximide,
methsuccimide, carbamazepine, valproic acid, gabapentin, topiramate,
felbamate,
and phenobarbital); muscle relaxing agents (e.g., baclofen, carisoprodol,
chlorzoxazone, cyclobenzaprine, dantrolene sodium, metaxalone, orphenadrine,
pancuronium bromide, and tizanidine); antipsychotic agents (e.g.,
phenothiazine,
chlorpromazine, fluphenazine, perphenazine, prochlorperazine, thioridazine,
trifluoperazine, haloperidol, droperidol, pirnozide, clozapine, olanzapine,
risperidone,
quetiapine, ziprasidone, melperone, and paliperidone); antianxiolitic agents
(e.g.,
lorazepam, alprazolam, clonazepam, diazepam, buspirone, meprobarnate, and
flunitrazepam); antihyperactive agents (e.g., methylphenidate, amphetamine,
and
dextroamphetamine); antihypertensive agents (e.g., alpha-methyldopa,
chlortalidone,
reserpine, syrosingopine, rescinnamine, prazosin, phentolamine, felodipine,
propanolol, pindolol, labetalol, clonidine, captopril, enalapril, and
lisonopril); anti-
neoplasia agents (e.g., taxol, actinomycin, bleomycin A2, mitomycin C,
daunorubicin,
doxorubicin, epirubicin, idarubicin, and mitoxantrone); soporific agents
(e.g.,
zolpidem tartrate, eszopiclone, ramelteon, and zaleplon); tranquilizer agents
(e.g.,
alprazolam, clonazepam, diazepam, flunitrazepam, lorazepam, triazolam,
chlorpromazine, fluphenazine, haloperidol, loxapine succinate, perphenazine,
prochlorperazine, thiothixene, and trifiuoperazine); decongestant agents
(e.g.,
ephedrine, phenylephrine, naphazoline, and tetrahydrozoline); beta blockers
(e.g.,
levobunolol, pindolol, timolol maleate, bisoprolol, carvedilol, and
butoxamine); alpha
blockers (e.g., doxazosin, prazosin, phenoxybenzamine, phentolamine,
tamsulosin,
alfuzosin, and terazosin); non-steroidal hormones (e.g., corticotropin,
vasopressin,
CA 02868416 2014-09-24
WO 2013/158810 PCT/US2013/037046
12
oxytocin, insulin, oxendolone, thyroid hormone, and adrenal hormone); erectile
disfunction improvement agents; herbal agents (e.g., glycyrrhiza, aloe,
garlic, nigella
sativa, rauwolfia, St John's wort, and valerian); enzymes (e.g., lipase,
protease,
amylase, lactase, lysozyme, and urokinase); humoral agents (e.g.,
prostaglandins,
natural and synthetic, for example, PGE1, PGE2alpha, PGF2alpha, and the PGE1
analog misoprostol); psychic energizers (e.g., 3-(2-aminopropy)indole and 3-(2-
aminobutyl)indole); nutritional agents; essential fatty acids; non-essential
fatty acids;
vitamins; minerals; and combinations thereof.
[0036] Any of the above-mentioned APIs may be incorporated in the
composition described herein in any suitable form, such as, for example, as a
pharmaceutically acceptable salt, uncharged or charged molecule, molecular
complex, solvate or anhydrate, and, if relevant, isomer, enantiomer, racemic
mixture,
and/or mixtures thereof. Furthermore, the API may be in any of its
crystalline, semi-
crystalline, amorphous, or polymorphous forms.
[0037] In one embodiment, the API present in the composition may
have a potential for abuse. For example, the API may be an opioid analgesic
agent,
a stimulant agent, a sedative agent, a hypnotic agent, an antianxiolitic
agent, or a
muscle relaxing agent.
[0038] In another embodiment, the API present in the composition may
be a combination of an opioid analgesic and a non-opioid analgesic. Suitable
opioid
and non-opioid analgesics are listed above.
[0039] In exemplary embodiments, the API in the composition may be
an opioid analgesic. Preferred opioid analgesics include oxycodone,
oxymorphone,
hydrocodone, hydromorphone, codeine, and morphine.
[0040] The amount of API(s) in the composition can and will vary
depending upon the active agent. In embodiments in which the API is an opioid
analgesic, the amount of opioid in the composition may range from about 2 mg
to
about 160 mg. In various embodiments, the amount of opioid in the composition
may range from about 2 mg to about 10 mg, from about 10 mg to about 40 mg,
from
about 40 mg to about 80 mg, or from about 80 mg to about 160 mg. In certain
embodiments, the amount of opioid in the composition may be about 5 mg, 7.5
mg,
mg, 12.5 mg, 15 mg, 17.5 mg, 20 mg, 22.5 mg, 25 mg, 27.5 mg, 30 mg, 32,5 mg,
35 mg, 37.5 mg, 40 mg, 45 mg, 50 mg, 60 mg, 70 mg, 80 mg, 100 mg, 120 mg, 140
mg, or 160 mg.
CA 02868416 2014-09-24
WO 2013/158810 PCT/US2013/037046
13
[0041] In embodiments in which the opioid is oxycodone
hydrochloride,
the total amount of oxycodone hydrochloride present in the pharmaceutical
composition may range from about 2 mg to about 80 mg. In certain embodiments,
the amount of oxycodone hydrochloride in the pharmaceutical composition may
range from about 2 mg to about 10 mg, from about 10 mg to about 30 mg, or from
about 30 mg to about 80 mg. In exemplary embodiments, the amount of oxycodone
hydrochloride present in the pharmaceutical composition may be about 5 mg,
about
mg, about 15 mg, about 20 mg, about 30 mg, about 40 mg, about 60 mg, or about
80 mg.
[0042] In embodiments in which the plaid is oxymorphone
hydrochloride, the total amount of oxymorphone hydrochloride present in the
pharmaceutical composition may range from about 2 mg to about 80 mg. In
certain
embodiments, the amount of oxymorphone hydrochloride present in the
pharmaceutical composition may range from about 2 mg to about 10 mg, from
about
10 mg to about 30 mg, or from about 30 mg to about 80 mg. In exemplary
embodiments, the amount of oxymorphone hydrochloride present in the
pharmaceutical composition may be about 5 mg, about 10 mg, about 20 mg, about
30 mg, about 40 mg, about 60 mg, or about 80 mg.
(vii) Optional excipients
[0043] In various embodiments, the pharmaceutical composition
disclosed herein may further comprise at least one additional pharmaceutically
acceptable excipient. Non-limiting examples of suitable excipients include
lubricants,
disintegrants, binders, fillers, diluents, antioxidants, chelating agents,
flavoring
agents, coloring agents, taste masking agents, and combinations thereof.
[0044] In one embodiment, the excipient may be a lubricant. Non-
limiting examples of suitable lubricants include magnesium stearate, calcium
stearate, zinc stearate, hydrogenated vegetable oils, sterotex,
polyoxyethylene
monostearate, polyethylene glycol, sodium stearyl fumarate, sodium benzoate,
sodium lauryl sulfate, magnesium lauryl sulfate, light mineral oil, and
combinations
thereof. In a preferred embodiment, the composition may comprise magnesium
stearate as a lubricant.
[0045] In another embodiment, the excipient may be a disintegrant
or a
superdisintegrant. The disintegrant or superdisintegrant may not affect
disintegration
CA 02868416 2014-09-24
WO 2013/158810 PCT/US2013/037046
14
of the composition in the typical sense, but may improve hardness of the solid
dose
compositions disclosed herein. Suitable disintegrants include, without limit,
starches
(such as corn starch, potato starch, and the like), pregelatinized and
modified
starches thereof, micro-crystalline cellulose, alginates, sodium starch
glycolate, and
gums (such as agar, guar, locust bean, karaya, pectin, and tragacanth). Non-
limiting
examples of suitable superdisintegrants include crospovidine, croscarmellose
sodium, sodium starch glycolate, low substituted hydroxypropyl cellulose, and
combinations thereof. In one preferred embodiment, the composition may
comprise
crospovidine as a superdisintegrant. In another preferred embodiment, the
composition may comprise F-MELT , a proprietary blend of carbohydrates,
disintegrants, and inorganic ingredients, as a superdisintegrant.
100461 In a further embodiment, the excipient may be a binder.
Suitable binders include, but are not limited to, starches, pregelatinized
starches,
gelatin, polyvinylpyrolidone, cellulose, methylcellulose, sodium
carboxymethylcellulose, ethylcellulose, polyacrylamides,
polyvinyloxoazolidone,
polyvinylalcohols, C12-C18 fatty acid alcohol, polyethylene glycol, polyols,
saccharides, oligosaccharides, polypeptides, peptides, and combinations
thereof.
[0047] In another embodiment, the excipient may be a filler. Suitable
fillers include carbohydrates, inorganic compounds, and polyvinylpyrrolidone.
By
way of non-limiting examples, the filler may be calcium sulfate, calcium
phosphate,
calcium silicate, microcrystalline cellulose, starch, modified starches,
lactose,
sucrose, mannitol, sorbitol, or combinations thereof.
[0048j In another embodiment, the excipient may include a diluent.
Non-limiting examples of diluents suitable for use include pharmaceutically
acceptable saccharides such as sucrose, dextrose, lactose, microcrystalline
cellulose, fructose, xylitol, and sorbitol; polyhydric alcohols; starches; pre-
manufactured direct compression diluents; and mixtures of any of the
foregoing.
100491 In yet another embodiment, the excipient may be an antioxidant.
Suitable antioxidants include, without limit, ascorbyl palmitate, butylated
hydroxyanisole, a mixture of 2 and 3 tertiary-butyl-4-hydroxyanisole,
butylated
hydroxytoluene, sodium isoascorbate, dihydroguaretic acid, potassium sorbate,
sodium bisulfate, sodium rnetabisulfate, sorbic acid, potassium ascorbate,
vitamin E,
4-chloro-2,6-ditertiarybutylphenol, alphatocopherol, and propylgallate, and
combinations thereof.
CA 02868416 2014-09-24
WO 2013/158810
PCT/US2013/037046
[0050] In an alternate embodiment, the excipient may be a chelating
agent. Non-limiting examples of suitable chelating agents include
ethylenediamine
tetracetic acid (EDTA) and its salts, N-(hydroxy-
ethyl)ethylenediaminetriacetic acid,
nitrilotriacetic acid (NIA), ethylene-bis(oxyethylene-nitrilo)tetraacetic
acid, 1,4,7,10-
tetraazacyclodo-decane-N,N',N",N"1-tetraacetic acid, 1,4,7,10-tetraaza-
cyclododecane-N,N',N"-triacetic acid, 1,4,7-tris(carboxymethyl)-10-(2'-
hydroxypropyl)- 1,4,7,10-tetraazocyclodecane, 1,4,7-triazacyclonane-N,N',N"-
triacetic acid, 1,4,8,11 -tetraazacyclotetra-decane-N,W,N",Nm-tetraacetic
acid;
diethylenetriamine-pentaacetic acid (DTPA), ethylenedicysteine,
bis(aminoethanethiol)carboxylic acid, triethylenetetraamine-hexaacetic acid,
1,2-
diaminocyclohexane-N,N,N',N'-tetraacetic acid, and combinations thereof.
[0051] In a further embodiment, the excipient may be a flavoring
agent.
Flavoring agents may be chosen from synthetic flavor oils and flavoring
aromatics
and/or natural oils, extracts from plants, leaves, flowers, fruits, and
combinations
thereof.
[0052] In still another embodiment, the excipient may be a coloring
agent. Suitable color additives include food, drug and cosmetic colors (FD&C),
drug
and cosmetic colors (D&C), or external drug and cosmetic colors (Ext. D&C).
[0053] In yet another embodiment, the excipient may be a taste-
masking agent. Taste-masking materials include cellulose hydroxypropyl ethers
(H PC); low-substituted hydroxypropyl ethers (L-HPC); cellulose hydroxypropyl
methyl ethers (HPMC); methylcellulose polymers and mixtures thereof; polyvinyl
alcohol (PVA); hydroxyethylcelluloses; carboxymethylcelluloses and salts
thereof;
polyvinyl alcohol and polyethylene glycol copolymers; monoglycerides or
triglycerides; polyethylene glycols; acrylic polymers; mixtures of acrylic
polymers with
cellulose ethers; cellulose acetate phthalate; and combinations thereof.
[0054] The amount of excipient(s) in the composition can and will
vary
depending upon the identity and amounts of the components of the composition
and
API(s) detailed above.
'viii) Optional film coating
[0055] In other embodiments, the pharmaceutical composition may
further comprise an optional film coating. Typically, the film coating
comprises
water-soluble polymer(s) and does not affect the immediate release or tamper
CA 02868416 2014-09-24
WO 2013/158810 PCT/US2013/037046
16
resistant properties of the composition. The film coating may provide moisture
protection, enhanced appearance, increased mechanical integrity, improved
swallowability, improved taste, and/or masking of odors.
[0056] Film coatings are well known in the art, e.g., they are
commercially available under the tradename OPADRY . Typically, a film coating
comprises at least one water-soluble polymer and at least one plasticizer. Non-
limiting examples of suitable polymers include hydroxypropyl methylcellulose,
hydroxypropyl cellulose, hydroxypropyl ethylcellulose, ethylcellulose,
methylcellulose, cellulose acetate phthalate, microcrystalline cellulose and
carrageenan, acrylic polymers, polyvinyl alcohol, anionic and cationic
polymers of
methacrylic acid, copolymers of methacrylates, copolymers of acrylates and
methacrylates, copolymers of ethacryl ate and methylmethacrylate, polyvinyl
acetate
phthalate, and shellac. Examples of suitable plasticizers include, without
limit,
triethyl citrate (TEC), acetyltriethyl citrate (ATEC), acetyl tri-n-butyl
citrate (ATBC),
dibutyl sebacate, diethyl phthalate, and triacetin. The film coating may
optional
comprise additional agents such as a coloring agent, a filler, a flavoring
agent, a
taste-masking agent, a surfactant, an anti-tacking agent, and/or an anti-
foaming
agent. Suitable examples of these agents are well known in the art and/or are
detailed above.
(ix) Exemplary embodiments
[0057] In one exemplary embodiment, the pharmaceutical composition
may be a non-effervescent formulation in which the low molecular weight water-
soluble polymer may be a polyethylene oxide having a molecular weight of about
100,000 Da; the polyglycol may be a poloxamer (e.g., Pluronic F68 and/or
Pluronic
F127); the polysaccharide may be xanthan gum; and the clay mineral may be
sodium bentonite or a combination of sodium bentonite and talc. The
composition
may further comprise a superdisintegrant and a lubricant. The API may be an
opioid
chosen from oxycodone, oxymorphone, hydrocodone, hydromorphone, codeine, and
morphine. The composition of a non-effervescent formulation is shown in the
Table
A below:
Table A. Exemplary Non-Effervescent Formulation.
Ingredient I % w/w Range I Function
CA 02868416 2014-09-24
WO 2013/158810 PCT/US2013/037046
17
API 5-20 Active
PEO 100,000 g/mol 20¨ 35 Physical Plasticity / Prevent
_ pulverization
Pluronic 10 ¨45 Emulsification / Prevent
pulverization
Xanthan Gum 2 ¨ 6 Emulsification
Na-Bentonite 5 ¨ 15 Disintegrant / Visual deterrent
Talc 0¨ 10 Disintegrant / Visual deterrent
Superdisintegrant (e.g., 0¨ 10 Disintegrant / Provides tablet
F-melt) hardness
Magnesium Stearate 1 Lubricant
[00581 In another exemplary embodiment, the pharmaceutical
composition may be an effervescent formulation in which the low molecular
weight
water-soluble polymer may be a polyethylene oxide having a molecular weight of
about 100,000 Da; the polyglycol may be a poloxamer (e.g., Pluronic F68 and/or
Pluronic F127); the polysaccharide may be xanthan gum; the clay mineral may be
sodium bentonite or a combination of sodium bentonite and talc; the base
component of the effervescent system may comprise sodium bicarbonate or a
combination of sodium bicarbonate and sodium carbonate; the acid component of
the effervescent system may comprise tartaric acid and a combination of
tartaric acid
and citric acid. The composition may further comprise a lubricant. The API may
be
an opioid chosen from oxycodone, oxymorphone, hydrocodone, hydromorphone,
codeine, and morphine. The composition of an effervescent formulation is shown
in
the Table B below:
Table B. Exemplary Effervescent Formulation.
Ingredient % ION Range Function
API 5 ¨ 20 Active
PEO 100,000 g/mol 30 ¨50 Physical Plasticity / Prevent
pulverization
Pluronic 10 ¨ 30 Emulsification / Prevent
pulverization
Xanthan Gum 2 ¨6 Emulsification
Na-Bentonite 5 - 15 Disintegrant / Visual deterrent
Talc 0 ¨ 10 Disintegrant / Visual deterrent
Base Component 10 ¨20 Effervescent component
Citric Acid Anhydrous 0 ¨ 15 Effervescent component /
Plasticizer
Tartaric Acid 5¨ 15 Effervescent component
Magnesium Stearate 1 Lubricant
(b) Dosage Forms
CA 02868416 2014-09-24
WO 2013/158810
PCT/US2013/037046
18
[0059] The physical form of the pharmaceutical compositions
disclosed
herein can and will vary. In general, the pharmaceutical compositions are
solid
dosage forms for oral administration. Suitable solid dosage forms include
tablets,
caplets, granules, pills, and capsules. Such dosage forms may be prepared
using
conventional methods known to those in the field of pharmaceutical formulation
and
described in the pertinent texts, e.g., in Gennaro, A. R., editor. "Remington:
The
Science & Practice of Pharmacy", 21st ed., Williams & Williams, and in the
"Physician's Desk Reference", 2006, Thomson Healthcare.
[0060] In preferred embodiments, the solid dosage form may be a
tablet. Non-limiting types of tablets include coated tablets, uncoated
tablets,
compressed tablets, compacted tablets, molded tablets, layered tablets,
bilayer
tablets, extruded tablets, multiparticle tablets, monolithic tablets, and
matrix tablets.
In exemplary embodiments, the pharmaceutical composition may be a solid dosage
form comprising a tablet.
[0061] In general, the tablet has sufficient mechanical strength
and/or
resiliency that it is difficult to crush into a powder. The mechanical
strength of the
tablet may be quantified its hardness or crushing strength, friability, and/or
tensile
strength.
[0062] In preferred embodiments, the tablet may have a hardness or
crushing strength of at least about 7 kilopond (kp). In various embodiments,
the
tablet may have a hardness or crushing strength that ranges from about 7 kp to
about 10 kp, from about 10 kp to about 15 kp, from about 15 kp to about 20 kp,
from
about 20 kp to about 25 kp, or greater than 25 kp..
[0063] In general, the tablet has a friability of no greater than
about
1.0%, or more preferably no greater than about 0.5%. In certain embodiments,
the
tablet may have a friability of less than about 1.0%, less than about 0.5%,
less than
about 0.3%, less than about 0.2%, less than 'about 0.1%, less than about
0.05%, or
less than about 0.01%. In still another embodiment, the tablet may have a
friability
of zero.
(c) in Vitro Release Properties of the Composition
[0064] The pharmaceutical composition disclosed herein is
formulated
such that the API in the composition is rapidly released. Thus, the
composition is
CA 02868416 2014-09-24
WO 2013/158810
PCT/US2013/037046
19
termed an immediate release composition. As used herein, "immediate release"
generally refers to an average release of at least 70% of the API within 45
minutes.
[0065] The in vitro dissolution of the API from the composition
disclosed herein may be measured using an USP-approved release procedure. For
example, dissolution may be measured using an USP Type 2 paddle apparatus, at
a
paddle speed of 50 rpm or 100 rpm, and a constant temperature of 37 0.5 C.
The
dissolution procedure may be performed in the presence of 500 mL, 900 mL, or
1,000 mL of a suitable dissolution medium (e.g., having a pH from 1.0 to 6.8).
Non-
limiting examples of suitable dissolution media include water, phosphate
buffer (pH
6.8), acetate buffer (pH 4.5), and 0.1N HCI.
[0066] The pharmaceutical compositions disclosed herein provide
immediate release of the API. In some embodiments, the pharmaceutical
composition may have an average release of about 50%, 55%, 60%, 65%, 70%,
75%, 80%, 85%, 90%, 95%, or 99% of the API within about 45 minutes. In other
embodiments, the pharmaceutical composition may have an average release of
about 50%, 55%, 60%, 65%, 70%, 75%, 80%, 85%, 90%, 95%, or 99% of the API
within about 30 minutes.
(d) Abuse Deterrent Properties of the Composition
[0067] The blend of components in the pharmaceutical compositions
disclosed herein provides abuse deterrent or tamper resistant properties. For
example, the disclosed compositions are resistant to crushing, grinding,
cutting, or
pulverizing to form fine powders. The combination of the low molecular weight
water-soluble polymer and the polyglycol may contribute to the crush
resistance of
pharmaceutical compositions by imparting plastic properties to the solid
dosage
form. In some embodiments, the solid dosage compositions may form large waxy
flakes when subjected to various crushing/pulverizing means (e.g., such as a
pill
crusher, a tablet grinder, a hammer, and/or trituration with a mortar and
pestle). In
exemplary embodiments, the solid dosage compositions are plastic and cannot be
ground or pulverized into particles. When such compositions are subjected to
milling
(e.g., using a high-shear mill, a ball mill, a co-mill, pill crusher, a tablet
grinder, a
coffee grinder, a blender, a hammer, or another apparatus to reduce particle
size)
only large particles are formed.
CA 02868416 2014-09-24
WO 2013/158810
PCT/US2013/037046
[0068] In one embodiment, when the composition is milled for 9
minutes to form particles size, more than about 30%, 40%, 50%, 60%, 70%, 80%,
90%, or 95% of the particles have an average diameter of at least about 250
microns. In another embodiment, after 9 minutes of milling to form particles,
more
than about 30%, 40%, 50%, 60%, 70%, 80%, 90%, or 95% of the particles have an
average diameter of at least about 500 microns. Because the compositions
disclosed herein are resistant to forming fine powders, they deter abuse by
inhalation.
[0069] Additionally, the compositions, whether whole or
crushed/pulverized, form viscous colloidal dispersions when contacted with a
small
volume of a suitable solvent. The volume may be about 3 m1_, 5 mL, or 10 ml_.
Suitable solvents include water, alcohol solutions, acid mixtures, and the
like. The
viscosity of the dispersion prevents the material from being drawn through an
injection syringe needle. Additionally, the dispersion comprises clay mineral
particles that not only serve as visual deterrents, but also are difficult to
remove by
sedimentation or filtration and are large enough to restrict or block flow
though
injection needles. Consequently, the compositions disclosed herein are
resistant to
abuse by extraction, filtering, and/or injection.
(II) Processes for Preparing Solid Dosage Pharmaceutical Compositions
[0070] Another aspect of the disclosure encompasses processes for
preparing solid dosage forms of the pharmaceutical compositions disclosed
herein.
The processes comprise: (a) forming a mixture comprising at least one low
molecular weight water-soluble polymer, at least one polyglycol, at least one
polysaccharide, at least one clay mineral, and, optionally, an effervescent
system;
(b) forming a solid dosage unit from the mixture; and (c) heating the solid
dosage
unit to form the solid dosage form.
(a) Forming a mixture
[0071] The first step of the process comprises forming a mixture
comprising the components of the pharmaceutical composition, which are
detailed
above in section (I)(a). The mixture comprises at least one low molecular
weight
water-soluble polymer, at least one polyglycol, at least one polysaccharide,
at least
one clay mineral, a lubricant, and, optionally, an effervescent system. In
general, the
CA 02868416 2014-09-24
WO 2013/158810
PCT/US2013/037046
21
mixture further comprises at one API or a pharmaceutically acceptable salt
thereof.
The mixture components may be combined in any order or may be premixed in
various combinations before being combined together. For example, the
polyglycol
and the clay mineral may be blended together before being combined with the
rest of
the components. Similarly, the API may be combined with some of the components
before being combined with the rest of the components. Thus, a variety of
ordered
mixing schemes are possible.
[0072] In embodiments in which an effervescent formulation is
prepared, the mixture may be prepared by first mixing (e.g., hot-melt
granulating) the
acid component of the effervescent system with the polyglycol to form a
plurality of
polyglycol-coated acid component particles. Next, the plurality of polyglycol-
coated
acid particles may be mixed with the clay mineral to form a plurality of clay
mineral/polyglycol-coated particles. Lastly, the plurality of clay
mineral/polyglycol-
coated particles may be mixed with the rest of the components. The clay
mineral/polyglycol coating may protect the acid component of the effervescent
system from moisture and/or premature contact with the base component of the
effervescent system (see Example 3 below).
[0073] The mixture comprising the components of the composition may
be formed by mixing, roller mixing, drum mixing, shear mixing, dry blending,
chopping, milling, granulating, dry granulating (e.g., slugging or roller
compacting),
wet granulating (e.g., fluid bed granulating, high shear granulating), and
other mixing
techniques known in the art.
(b) Forming a solid dosage unit
[0074] The process further comprises forming the mixture from step
(a)
into a solid dosage unit. Suitable solid dosage units are described above in
section
(I)(b). Means of forming solid dosage units are well known in the art. In
exemplary
embodiments, the solid dosage unit may be a tablet. The tablet may be a
compression tablet, a molded tablet, a compacted tablet, or a pressed tablet.
In an
exemplary embodiment, the tablet may be formed by direct compression. The
shape
of the tablet may vary. Non-limiting tablet shapes include round, oval,
rectangular,
and triangular. The size and mass of the tablet may vary. In various
embodiments,
the mass of the tablet may be range from about 100 mg to about 1000 mg.
CA 02868416 2014-09-24
WO 2013/158810
PCT/US2013/037046
22
(c) Heating the solid dosage unit
[0075] The final step of the process comprises heating the solid
dosage
unit to yield the solid dosage form. This heating step dries and cures the
solid
dosage unit, wherein the cured solid dosage form may have improved properties
or
characteristics relative to an uncured solid dosage unit. For example, the
heating
step removes water from the solid dosage unit, therefore protecting the
effervescent
system in the solid dosage form from premature effervescence. The heating step
may plasticize the low molecular weight water-soluble polymer(s) and/or melt
the
polyglycol, thereby forming a porous matrix solid dosage form that has
increased
resistant to crushing/pulverization as well as more rapid release of the API.
[0076] In general, the solid dosage unit is heated at a temperature
of
less than about 90 C. In various embodiments, the solid dosage unit may be
heated
at a temperature from about 30 C to about 35 C, from about 35 C to about 40 C,
from about 40 C to about 45 C, from about 45 C to about 50 C, from about 50 C
to
about 55 C, from about 55 C to about 60 C, from about 60 C to about 65 C, from
about 65 C to about 70 C, from about 70 C to about 75 C, from about 75 C to
about
80 C, from about 80 C to about 85 C, or from about 85 C to about 90 C. In
exemplary embodiments, the heating temperature may range from about 50 C to
about 80 C.
[0077] The duration of the heating step can and will vary depending
upon the components of the composition. The duration of the heating step may
range from about 10 minutes to about 10 hours. In general, the higher the
temperature, the shorter the duration of time. In an exemplary embodiment, the
solid
dosage unit may be heated to a temperature from about 60 C to about 80 C for a
period of time ranging from about 1 hour to about 2 hours.
EXAMPLES
[0078] The following examples are included to illustrate, but not
to limit
the claimed pharmaceutical compositions and processes for making.
Example 1: Test Formulations
CA 02868416 2014-09-24
WO 2013/158810 PCT/US2013/037046
23
[0079] Two non-effervescent formulations (1, 2) and two effervescent
(3, 4) formulations were prepared and tested for immediate release dissolution
behavior and abuse deterrent (or tamper resistant) properties.
[0080] The components listed for each formulation were dry blended,
directly compressed into tablets using a single station hand press (Natoli
Engineering, St. Charles, MO) and a compression force of 425-475 units, and
cured
at 60-80 C for 1-2 hr.
[0081] The in vitro dissolution of oxycodone from the tablets was
measured in 500 mL phosphate buffer or water using an USP Apparatus 2
(paddles)
with a paddle speed of 50 rpm and a temperature of 37 C. The tablets were
placed
in sinkers to prevent flotation. Samples were removed at 15, 30, and 45 min
and
analyzed by HPLC for oxycodone hydrochloride.
[0082] Tamper resistance was tested by subjecting the tablets to
grinding and milling tests. For the grinding test, a tablet was placed between
two
aluminum sample pans and hit ten times to crush the tablet into a thin
pancake. The
pancaked tablet was then manually crumbled (it was observed whether the
material
was waxy and or sticky and how easy it was to break the tablet into smaller
fragments). The crumbles were then placed in a porcelain mortar and triturated
(the
material was monitored for pulverization, pilling, flaking, and/or sticking).
Milling was
only performed on tablets that show positive results for the grinding test.
For the
milling test, a tablet was placed in a hardness tester (Dr. Schleuniger
Pharmatron,
Manchester, NH; Model 6D) and flattened to a pancake. The flattened tablet was
collected and placed in an analytical mill (IKA Laboratories; 10A mill) and
milled for 1
minute intervals for 1, 3, 6, 9 min. The particle size was determined using
standard
means.
[0083] Table 1 presents the composition of non-effervescent
formulation 1. Table 2 present the in vitro dissolution data. Tamper
resistance tests
revealed that the formulation 1 tablets could not be pulverized, but formed
waxy flaky
materials when subjected to trituration.
Table 1. Composition of Non-effervescent Formulation 1,
Ingredient % (w/w) of Composition
Oxycodone
21
CA 02868416 2014-09-24
WO 2013/158810 PCT/US2013/037046
24
PEO 100,000 g/mol 20
Pluronic F68 35
Xanthan Gum 3
Sodium Bentonite 10
F-Melt 10
Magnesium Stearate 1
Table 2. Dissolution of Formulation 1.
Time Water ( /0) Phosphate Buffer (%)
15 min 53.5 49.9
30 min 79.4 82.5
45 min 87.5 97.8
[0084] Table 3 presents the composition of non-effervescent
formulation 2. Table 4 shows that this formulation clearly met the standard
for
immediate release (i.e., at least 70% released within 30 min or 45 min).
Tamper
resistance tests revealed that the tablets could not be pulverized, but formed
waxy
flaky materials when subjected to crushing.
Table 3. Com=osition of Non-effervescent Formulation 2.
, Ingredient % (w/w) of Composition
Oxycodone 20
PEO 100,000 g/mol 26
Pluronic F68 9.5
Pluronic F127 9.5
Xanthan Gum 3
Sodium Bentonite 16
Micronized Talc 5
Crospovidone XL-10 10
Magnesium Stearate 1
Table 4. Dissolution of Formulation 2.
Time Water (%) Phosphate Buffer (%)
15 min 66.7
30 min 88.2
45 min 96.1
[0085] Table 5 presents the composition of effervescent formulation 3,
and Table 6 shows that this formulation had immediate release. The tablets
were
hard and plastic. When milled for 9 min, 66% of the tablet retained a particle
size of
greater than 500 microns.
CA 02868416 2014-09-24
WO 2013/158810 PCT/US2013/037046
Table 5. Composition of Effervescent Formulation 3.
Ingredient % (w/w) of
Composition
Oxycodone 21
PEO 100,000 g/mol 20
Pluronic F68 19.25
Xanthan Gum 3
Sodium Bentonite 10
Effersoda 13.75
Citric Acid 4
Tartaric Acid 8
Magnesium Stearate 1
Table 6. Dissolution of Formulation 3.
Time Water (%) Phosphate Buffer
(/0)
15 min 68.0 71.7
30 min 87.4 94.2
45 min 88.8 95.8
[0086] Table 7 presents the
composition of effervescent formulation 4,
and Table 8 presents the in vitro release data. The tablets were hard and
plastic and
could not be pulverized, but formed waxy flaky materials when triturated. When
milled for 9 min, 66% of the tablet retained a particle size of greater than
500
microns.
Table 7. Composition of Effervescent Formulation 4.
Ingredient % (w/w) of
Composition
Oxycodone 21
PEO 100,000 g/mol 30
Pluronic F68 10
Xanthan Gum 3
Sodium Bentonite 15
Sodium Bicarbonate 10.58
Tartaric Acid 9.42
Magnesium Stearate 1
Table 8. Dissolution of Formulation 4.
Time Water (%) Phosphate Buffer
(%)
15 min 73.1 86.0
30 min 83.0 97.5
45 min 83.3 98.2
Example 2: Effect of Individual Components on Tablet Performance
CA 02868416 2014-09-24
WO 2013/158810 PCT/US2013/037046
26
[0087] The effective concentration range of each individual component
was analyzed in non-effervescent and effervescent formulations. The
formulations
were prepared and formed into tablets essentially as detailed above in Example
1.
The disintegration was tested using the standard paddle dissolution apparatus
as
detailed in Example 1, except disintegration was monitored at 30 min. At 30
min,
any remaining tablet was removed from the sinker, wiped off and weighed on a
standard balance to determine how much of the tablet was remaining. If the
tablet
had completely disintegrated before the 30 min mark, the time to complete
disintegration was recorded instead. The tamper resistance was monitored using
the grinding and milling tests detailed above in Example 1. The following
scale was
used to rank tamper resistance (0 = little or no resistance, 6 = excellent
tamper
resistance):
0 ¨ Tablets showed processing issues such as picking and capping.
1 ¨ Tablet is crumbly or brittle and can be completely or partially
pulverized.
2 ¨ Tablet is crumbly but forms flakes when attempting to pulverize.
3 ¨ Tablet is crumbly but forms waxy and/or sticky flakes when attempting to
pulverize.
4 ¨ Tablet is not crumbly but breaks down to large fakes when attempting to
pulverize.
¨ Tablet is plastic and does not break down by trituration.
6 ¨ Tablet is plastic and does not break down by trituration and does not
pulverize through milling.
[0088] The results are shown below in Tables 9-16. The results are
bracketed according to percent ranges. Abbreviations used in the tables are:
T&B
(talc and bentonite combined percentage), XG (xanthan gum), CA (citric acid),
Man
(mannitol), SB (co-processed sorbitol/glycerol), SA (sodium alginate), rem.
(remaining), TR (tamper resistance).
[0089] Polyox (PEO) 100,000 g/mol. Formulations were prepared that
contained from 0¨ 66% (w/w) of Polyox 100,000 g/mol. Tables 9 and 10 show the
results for non-effervescent and effervescent formulations, respectively.
These
studies revealed that Polyox 100,000 g/mol provided hardness and plasticity to
the
tablets.
Table 9. Effect of Various Concentrations of Polyox on Non-Effervescent
Formulations.
CA 02868416 2014-09-24
WO 2013/158810 PCT/US2013/037046
27
Table 9. Effect of Various Concentrations of Polyox on Non-Effervescent
Formulations.
Tamper Resistance Disintegration _
%
Polyox Too Approximate dissolution
Range TR Approximate
Amount Exceptions
rating in water at
Remaining 30 min .
30% rem. if 50%
>3% XG and/or > 5% Polyox with 5%
talc and/or > 5% talc and 10%
> 50% 5 sodium bentonite > 50% bentonite (TR Not tested
caused inadequate
properties
TR performance insufficient)
All samples tested in No CA, no Man, a
this range contained 7.5% bentonite -
a 40% 3 high levels of T&B. 3 Mostly > 50% <16% rem. (TR 50 ¨ 65%
samples w/out T&B properties
had better TR insufficient)
properties
All samples tested in
this range contained
high levels of T&B.
Either no talc or no
35% 3 > 30% Only F68 used. 50%
a
bentonite or no CA, No F127
no Man resulted in
better TR
performance
42% F68, no
F127, 0% T&B
Incorporation of more (good TR
than 6% XG, and/or > properties)
1% CA, and/or 38% F68, no
contained Pullulan, F127, 5%
and/or contained SB
a 30% 4 ' Mostly > 25% bentonite. (TR 75 ¨ 85%
and/or contained properties
man, and/or insufficient)
contained SA causes
poorer TR High T&B
performance (5/13.5%) (TR
properties
insufficient)
35% F68, no
F127, no talc, 5%
F-Melt (good TR
No F-Melt in properties)
combination with high 32% F68, no
T&B and/or w/ XG F127, no talc,
a. 20% 2 200 mesh, or Pullulan Mostly 20% < 19% bentonite 75 ¨ 80%
rem. <30%
or CA, and/or T&B a (good TR
20% results in worse properties)
TR properties 33% F68, no
F127, no talc,
10% F-Melt (good
TR properties)
0, 1, or
< 20% No Exceptions Not tested None Not tested
2
CA 02868416 2014-09-24
WO 2013/158810 PCT/US2013/037046
28
Table 9. Effect of Various Concentrations of Polyox on Non-Effervescent
Formulations.
0% 1 No Exceptions > 60% None Not
tested
Table 10. Effect of Various Concentrations of Polyox on Effervescent
Formulations.
Tamper Resistance Disintegration
Polyox Approximate % dissolution
TR Exceptions /
Range Amount Exceptions in water at
30
rating Explanations Remaining min
40% 5 No Exceptions Not Tested N/A 50 ¨
65%
40 ¨ 50% for
Fast low
3 for samples not disintegration if effervescent
30% 3, 4 containing CA and/or at least 20% of
none levels, > 80%
with <32% Polyox effervescent for high
materials used effervescent
levels
Fast Low
disintegration if
2 for samples not effervescent
20% 2, 4 at least 20% of > 87%
containing CA effervescentlevels not
tested
materials used
[0090] Pluronics. Formulations were prepared in which the total
concentration of Pluronic ranged from 0 ¨ 46% (w/w). Tables 11 and 12 present
the
tamper resistance and disintegration data for non-effervescent and
effervescent
formulations, respectively. Pluronics provided waxy properties to the tablets
and
aided in the formation of the non-filterable particle dispersion. It was found
that
disintegration and dissolution were highly dependent on the choice of Pluronic
(i.e.,
the tested Pluronics had the following order, from the slowest to the fastest:
F127 <
F108 < F87 5. F68). It was found that Pluronic levels below 10% negatively
affected
the strength of particle suspension.
Table 11. Effect of Various Concentrations of Pluronics on Non-Effervescent
Formulations.
Tamper Resistance Disintegration
App roxima
Pluronic te Amount
TR Exceptions /
dissolution
Range Explanations Remaining
rating Explanations in
water at
after 30 30 min
min
High Pluronic levels
improve waxy
34% properties of the
F68 only 3 ¨ 4 10% None 80¨ 85%
tablets. High Polyox
levels are however
needed to provide
CA 02868416 2014-09-24
WO 2013/158810
PCT/US2013/037046
29
Table 11. Effect of Various Concentrations of Pluronics on Non-Effervescent
Formulations.
sufficient plasticity
Samples containing Samples
CA, Pullulan, 200 Mesh containing > 25%
XG or > 3% XG 60 Bentonite and >
1 ¨ 2 13% 45 ¨
75%
Mesh or a 20% 4% XG
bentonite are more disintegrated more
brittle slowly
4 None 10 ¨ 33% _ None 75 ¨
80%
Samples containing
30% CA, Pullulan, 200 mesh
a
KG or > 3% XG 60
F68 only 0,2 15 ¨ 20% None 65 ¨
80%
mesh or a 20%
bentonite are more
brittle
33 ¨ 50% for
33 ¨ 50% samples with 1:1 50 ¨
60%
3 None
F68:F127, 20% for (only F68
or 20%
samples with only samples)
a20% F68
Not tested
F68 only. Samples with
(disintegra
0, 2 0 rating contained 19% Not tested N/A
tion too
Bentonite and CA slow)
Samples
80% Not
tested
containing_no T&B (disintegra
4 ¨ 5 None Samples tion
too
a. 10% 20 ¨ 60% containing talc
slow)
1:1 and/or bentonite
F127:F68 0 rating 10 ¨ 15%
talc 50% for samples
0,1 5 ¨ 50% 50 ¨
90%
1 rating ¨ T&B > 15% containing Na salts
or contained CA _
All formulations
contained > 50%
<10% 5 >60% None Not tested
Polyox and 3% CA and
5% bentonite
Not
Formulations had close
0% 4 extensively None 50%
to 30% bentonite tested
Table 12. Effect of Various Concentrations of Pluronics on Effervescent
Formulations.
Tamper Resistance Disintegration
Approxima
Pluronics te Amount
TR Exceptions /
dissolution
Range Explanations Remaining
rating Explanations in
water at
after 30 30 min
min
CA 02868416 2014-09-24
WO 2013/158810 PCT/US2013/037046
Contained > 20%
15 ¨ 20% effervescent Not
tested
Contained 20 ¨ 40% materials
20% 5 Polyox Contained < 10%
33% effervescent 50%
materials
Contained > 25%
0% effervescent > 85%
Contained 20 ¨ 40% materials
15% 5 Polyox Contained < 10%
30% effervescent 50%
materials
Contained > 25%
0% effervescent >50%
materials
Contained 25 ¨ 50% Contained 5 20%
Polyox. Sample with a effervescent
10% 4 ¨ 6 6 rating contained 10% materials or
F68, 35% Polyox, 20% 15¨ 30% contained > 25% 50 _ 75%
effervescent materials effervescent
materials but uses
F127 instead of
F68
Contained 30 ¨ 36%
<10% 5 ¨6 0 ¨ 15% None BO ¨
85%
Polyox.
[0091] Xanthan Gum. Concentration test range was from 0¨ 12%
(w/w) in the formulations. Table 14 presents the results for the non-
effervescent
formulations. It was found that higher xanthan gum concentrations incorporated
in
the formulations, resulted in stronger suspensions with greater abuse
deterrent
properties. A minimum of 3% (w/w) was needed in the formulation. However, the
level of xanthan gum inversely correlated with disintegration and dissolution
rate at
levels > 3%.
Table 13. Effect of Various Concentrations of Xanthan Gum on Non-Effervescent
Formulations.
Tamper Resistance Disintegration
ok
Approximate
XG
dissoluti
TR
Range Explanations Amount Exceptions / on in
rating Remaining Explanations water at
after 30 min
30 min
XG at high levels Not
> 6% 1 ¨ 2 increases tablet 50 ¨ 70% none
tested
brittleness
6% 5 Contained > 30% 80% 1 sample containing Not
CA 02868416 2014-09-24
WO 2013/158810 PCT/US2013/037046
31
Table 13. Effect of Various Concentrations of Xanthan Gum on Non-Effervescent
Formulations.
Polyox and 5% CA and 32% F68 and 10% tested
no bentonite and talc bentonite achieved
20% rem.
Samples containing
Contained 10 ¨ 15%
1 30 ¨50% 10% bentonite, 30%
talC or bentonite F68, no talc _
Generally contained >
3 30% F68 and Polyox 15 ¨ 300/0 none 75 ¨
and not more than 10% 85%
> 3% bentonite
Contain 30 ¨ 45% F68
2 and 19 ¨ 20% 30 ¨ 60% none 50%
bentonite
Disintegration and
TR performance dissolution are 40 ¨
- 3% varies independent of XG varies
governed by other 92 /0
levels 5 3% components at XG
levels 5 3%
[0092] For effervescent formulations, xanthan gum levels were held
constant at 3% (w/w) with two exceptions of 6%. It was found that 6% could be
used, since high levels of Polyox allowed for incorporation of a larger
quantity of
materials such as xanthan gum, to offset the brittleness of the xanthan gum.
These
formulations however, showed insufficient dissolution, even with 20%
effervescent
materials (e.g., 73% in 30 min).
[0093] Micronized Talc. Concentration test range was from 0 ¨18%
(w/w) in the formulations. Table 14 presents the tamper resistance and
disintegration
data for non-effervescent formulations. Talc worked as a glidant and reduced
processing issues due to the Pluronics. Talc also improved tablet
disintegration time
but at high levels negatively impacted TR properties.
Table 14. Effect of Various Concentrations of Micronized Talc on Non-
Effervescent
Formulations.
Tamper Resistance Disintegration
alc
Approximate
T dissoluti
TR Amount Exceptions /
Range Explanations on in
rating Remaining Explanations
water at
after 30 min
30 min
15% achieved
a 2
High levels of Talc impart
15 ¨ 6 0 Vo through use of 30% Not
15%
brittleness F68 and 23%
tested
Polyox with 18% talc
a 10% 3 Contained at least 29% 30¨ 50%
None 75%
CA 02868416 2014-09-24
WO 2013/158810 PCT/US2013/037046
32
Polyox and 5 20% of 1:1
F127:F68
Either contained CA and Samples also
containing 5¨ 15%
Man or had < 30% Not
2 30 ¨ 50% bentonite and <
Polyox and > 16% of 1:1 tested
28% Polyox had 0 ¨
F127:F68 20% rem. at 30 min
Contained > 50% Polyox
and 3% CA and 5 ¨ 10% Samples containing Not
4 Pluronics or 23 ¨ 33% 50 ¨ 75% 23 ¨ 33% Polyox
tested
Polyox and 23% had 20 ¨ 30% rem.
Pluronics and no CA
a 56/0
Contained 3 ¨ 5% 40 ¨
Samples also contained 30¨ 60% CA and 5 ¨ 10% 75%
2 5 ¨ 18% bentonite or > Man
3% XG Did not contain CA 65 ¨
¨ 20% or Man 92%
Disintegration not
0 ¨ . TR not markedly affected 0 ¨ 80%
50 ¨
5% varies significantly driven
by talc itself in this range 85%
by talc in this range
[0094] Only a 5% level of
talc was investigated in effervescent tablets.
In these formulations, Polyox levels were at 25¨ 35% and effervescent
materials
were present at > 40%. TR performance for these tablets was ranked at 4 ¨5
with
complete disintegration being achieved at 30 min.
[0095] Sodium Bentonite.
The concentration range tested was 0-32%
(w/w). Tables 15 and 16 present the tamper resistance and disintegration data
for
non-effervescent and effervescent formulations, respectively. Sodium bentonite
worked somewhat as a glidant, improving powder flow in bulk blends. Due to its
nature of swelling to multiple times its dry volume in water, it also improved
tablet
disintegration time. At high levels however it negatively impacted TR
properties.
Table 15. Effect of Various Concentrations of Sodium Bentonite on Non-
Effervescent
Formulations.
Tamper Resistance Disintegration
Bentonite Approximat
TR e Amount
Exceptions / dissolution
Range Explanations
rating Remaining
Explanations in water at
after 30 min 30 min
Poor intactness of
High bentonite levels tablets rendered
a. 20% 0, 2 impart brittleness to Not
tested disintegration and Not tested
tablets dissolution testing
invaluable
All samples
a 15% 2 20 ¨ 50% None 75%
contained 15%
CA 02868416 2014-09-24
WO 2013/158810
PCT/US2013/037046
33
bentonite and 18 ¨
23% Pluronics or
19% bentonite and
32% Pluronics
1 ¨ Samples
containing < 30%
Pluronics Samples containing
1, 3 0 ¨ 33% > 3% XG were 45 ¨ 80%
3 ¨ Samples slower (66%)
containing > 30%
Pluronics
Disintegration and
Less brittle, no dissolution largely 50 ¨
80%
10% 3 ¨ 4 6 ¨ 33%
crumbling governed by other
excipients
Less brittle, no 50 ¨
75%
Tablets with talc >
5% 3 ¨ 5 crumbling except for
20 ¨ 60% 5% performed (not
extensive'
samples with talc >
better (15% rem)
5% y
studied)
Generally good TR 85%
properties. Contained
(exception
45¨ 50% Polyox, High
Polyox causes described
0% 4 ¨ 5 30 ¨ 80%
except one sample slow
disintegration under TR
with 32% Polyox and
Explanatio
42% Pluronics ns)
Table 16. Effect of Various Concentrations of Sodium Bentonite on Effervescent
Formulations.
Tamper Resistance Disintegration
Approximate
Bentonite
TR Amount Exceptions / dissolution
Range Explanations
rating Remaining Explanations in
water at
after 30 min 30 min
Disintegration 83% for
Samples contained time was highly samples
> 10% 5 30% Polyox and 0 ¨ 80% dependent on 20%
S 10% F68 effervescent effervescent
material levels materials
Samples with > Samples with 87%
for a
30% Polyox had only
CA and no Sample with
plastic properties. TA or with Polyox 2:1
TA:CA
0 ¨ 20%
Samples with < > 34% showed and 20%
30% Polyox slower Polyox and
contained z 4% CA disintegration 20% F68
10% Disintegration
and dissolution
Contained only TA are mainly
4 0 ¨ 33% 50 ¨
85%
(no CA) governed by
effervescent
material levels
All samples Disintegration
contained 25 ¨ and dissolution
<10% 5 0 ¨ 40% 65 ¨ 85%
50% Polyox and 5 are mainly
10% Pluronics governed by
CA 02868416 2014-09-24
WO 2013/158810 PCT/US2013/037046
34
Table 16. Effect of Various Concentrations of Sodium Bentonite on Effervescent
Formulations.
effervescent
material levels
Example 3: Stabilizing the Effervescent Components
[0096] The effervescent formulations are susceptible to premature
effervescence under conditions of high humidity. Such formulations may have a
reduced shelf-life and decreased stability. The following example details a
process
for coating the acid component of an effervescent system to reduce moisture
sensitivity and lower the likelihood of premature effervescence.
[0097] L-(+)-tartaric acid was hot-melt granulated with Kolliphor P 407
(Pluronic F127). The materials were blended in a water-jacketed granulator
until the
product temperature reached 60 C. The material was then removed from the
granulation bowl and allowed to cool to room temperature, at which point it
was
sieved through a 20 mesh screen to break down any agglomerates. FIG. 1A
presents a SEM image of L-(+)-tartaric acid particles and FIG. 1B presents a
similar
image of tartaric acid particles that are evenly coated with Pluronic F127.
The
coating appears have some fractures, which are likely due to the breaking of
agglomerates during the sieving process.
[0098] The Pluronic-coated tartaric acid particles were then blended
with talc, which sticks to the surface of the particles. FIG. 1C present a SEM
image
of the talc-coated particles. Elemental mapping of the coated particles
revealed that
the majority of the particles' surfaces were covered with talc, with limited
Pluronic
F127-coated surfaces visible (see FIG. 2).
[0099] The Pluronic Fl 27-talc coating formed a moisture barrier over
the tartaric acid particles, preventing interaction of tartaric acid with
water and
sodium bicarbonate. Dynamic vapor sorption studies (DVS) revealed that tablets
comprising the coated tartaric acid particles had less moisture sensitivity
that tablets
comprising regular tartaric acid. The DVS data are presented in Table 17.
Weight
gain indicates moisture sorption by the tablet, and weight loss indicates the
onset of
the stability-compromising effervescent reaction. These results show that the
use of
the coated tartaric acid allowed for more moisture sorption to occur without
effervescence being initiated immediately. Even when weight loss was initiated
in
the formulation containing the tartaric acid coated with Pluronic, the weight
loss was
CA 02868416 2014-09-24
WO 2013/158810 PCT/US2013/037046
slower than in the formulation with regular tartaric acid. These data indicate
that
formulations comprising coated tartaric acid particles had slower effervescent
reactions during tablet storage and the coating provided greater moisture
protection.
Table 17. Dynamic Vapor Sorption Results.
Condition Regular tartaric acid and Coated tartaric acid and
sodium bicarbonate sodium bicarbonate
1.3% total weight gain over 50
C, 50% RH 1.2% weight gain over 36 hrs
hrs
2.3% total weight gain followed
40 C, 60% RH by 3.5% total weight loss over 40 2.4% weight gain over
11.4 hrs
hrs
RH
40 C 67 0.8% total weight gain followed 3.5% weight gain
followed by 2%
, /o
by 3.4% weight loss over 17 hrs weight loss over 67 hrs
